Furthermore, the preclinical works which unravel the effects of GLP-1 in ocular dynamics and the preclinical literature regarding GLP-1RA use in the management of several neuro-ophthalmic conditions, including diabetic retinopathy (DR), glaucoma, and idiopathic intracranial hypertension (IIH) are discussed
The cardiovascular safety of GLP-1 agonists has been firmly established following a series of randomized clinical trials, such as SUSTAIN-6, HARMONY and REWIND (Marso et al., 2016)
What does Ozempic do to your organs
FMI's analysis of the GLP-1 receptor agonist market in Asia-Pacific consists of country-wise assessment including China, India, Japan, and South Korea
In: Sattler S, Kennedy-Lydon T (eds) The immunology of cardiovascular homeostasis and pathology